Skip to main content
SpringerLink
Log in

Focal Therapy for Prostate Cancer: Pending Questions

  • Invited Commentary
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Focal therapy (FT) represents a potential shift in clinical practice by featuring a tissue-sparing approach for prostate cancer (PCa) treatment. It stands midway between active surveillance (AS) and more aggressive options like radical prostatectomy (RP) or radiotherapy. The field has enormously evolved in the last few years but there are still pending questions to answer in the future. The manuscript overlooks FT in terms of indications, available energies, situation of tumor microenvironment, follow-up, re-interventions, and the future of this approach for PCa.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology. 2002;60(1):109–14.

    Article  PubMed  Google Scholar 

  2. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008;26(5):500–5.

    Article  PubMed  Google Scholar 

  3. de la Rosette J, Ahmed H, Barentsz J, Johansen TB, Brausi M, Emberton M, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010;24(5):775–80.

    Article  PubMed  Google Scholar 

  4. Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, et al. Focal therapy: patients, interventions, and outcomes—a report from a consensus meeting. Eur Urol. 2015;67(4):771–7.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Muller BG, van den Bos W, Pinto PA, de la Rosette JJ. Imaging modalities in focal therapy: patient selection, treatment guidance, and follow-up. Curr Opin Urol. 2014;24(3):218–24.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Linares Espinós E, Barret E, Sivaraman A, Pérez-Reggeti JI, Sánchez-Salas R, Rozet F, Galiano M, Cathelineau X. Localized prostate cancer Focal Therapy: “A la carte” Model. Arch Esp Urol. 2016

  7. Lindner U, Weersink RA, Haider MA, Gertner MR, Davidson SR, Atri M, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol. 2009;182(4):13717.

    Article  Google Scholar 

  8. Gladwell, Malcolm. The tipping point – How little things can make a difference. Ed. Little, Brown and Company (2000). Print.

  9. Walz J et al. Committee1 Diagnosis of Prostate Cancer and Selection for Focal Therapy. In: Image-Guided Therapies for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Sanchez-Salas, R and Desai, M. [eds.] Melbourne, Australia. October 15–18. Available at: http://www.siu-urology.org/society/siu-icud. Forthcoming October 2016.

  10. van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A, Cussenot O, et al. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol. 2015;33(7):907–16. doi:10.1007/s00345-015-1603-7.Epub2015Jun.

    Article  CAS  PubMed  Google Scholar 

  11. Ahmed HU, Dickinson L, Charman S, Weir S, McCartan N, Hindley RG, et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol. 2015;68(6):927–36. doi:10.1016/j.eururo.2015.01.030.

    Article  PubMed  Google Scholar 

  12. Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Barret E, Baumunk D, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Dominguez-Escrig J, Eggener S, Ganzer R, Ghai S, Gill IS, Gupta RT, Henkel TO, Hohenfellner M, Jones JS, Kahmann F, Kastner C, Köhrmann KU, Kovacs G, Miano R, van Moorselaar RJ, Mottet N, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sanchez-Salas R, Schostak M, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJ. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol. 2016 Feb 18.

  13. Muller BG, van den Bos W, Brausi M, Fütterer JJ, Ghai S, Pinto PA, et al. Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World J Urol. 2015;33(10):1503–9. doi:10.1007/s00345-014-1475-2.

    Article  CAS  PubMed  Google Scholar 

  14. van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, et al. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol. 2014;65(6):1078–83. doi:10.1016/j.eururo.2014.01.001.

    Article  PubMed  Google Scholar 

  15. Muller BG, Fütterer JJ, Gupta RT, Katz A, Kirkham A, Kurhanewicz J, et al. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int. 2014;113(2):218–27. doi:10.1111/bju.12243.

    Article  PubMed  Google Scholar 

  16. Ho R, Siddiqui MM, George AK, Frye T, Kilchevsky A, Fascelli M, et al. Preoperative multiparametric magnetic resonance imaging predicts biochemical recurrence in prostate cancer after radical prostatectomy. PLoS One. 2016;11(6):e0157313. doi:10.1371/journal.pone.0157313.eCollection 2016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Barret et al. Committee 3 Imaging in localized Prostate Cancer. Multiparametric Magnetic Resonance Imaging. In: Image-Guided Therapy for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Sanchez-Salas, R and Desai, M. [eds.] Melbourne, Australia. October 15–18, 2015. Available at: http://www.siu-urology.org/society/siu-icud. Forthcoming October 2016.

  18. Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol. 2013;63(1):125–40.

    Article  PubMed  Google Scholar 

  19. Siddiqui MM, George AK, Rubin R, Rais-Bahrami S, Parnes HL, Merino MJ, Simon RM, Turkbey B, Choyke PL, Wood BJ, Pinto PA. Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. J Natl Cancer Inst. 2016 Apr 29;108(9). pii: djw039. doi:10.1093/jnci/djw039. Print 2016 Sep.

  20. Konety et al. Committee 3 Prostatic biopsies: available techniques and approaches. In: Image-Guided Therapy for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Sanchez-Salas, R and Desai, M. [eds.] Melbourne, Australia. October 15–18, 2015. Available at: http://www.siu-urology.org/society/siu-icud. Forthcoming October 2016.

  21. Barret E, Ahallal Y, Sanchez-Salas R, Galiano M, Cosset JM, Validire P, et al. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol. 2013;63(4):618–22. doi:10.1016/j.eururo.2012.11.057.

    Article  CAS  PubMed  Google Scholar 

  22. Perez-Reggeti JI, Sanchez-Salas R, Sivaraman A, Linares Espinos E, de Gracia-Nieto AE, Barret E, Galiano M, Rozet F, Fregeville A, Renard-Penna R, Cathala N, Mombet A, Prapotnich D, Cathelineau X. High intensity focused ultrasound with Focal-One® device: Prostate-specific antigen impact and morbidity evaluation during the initial experience. Actas Urol Esp. 2016 Aug 16.

  23. Durand M, Barret E, Galiano M, Rozet F, Sanchez-Salas R, Ahallal Y, Macek P, Gaya JM, Cerruti J, Devilliers H, Loeffler J, Amiel J, Vallancien G, Cathelineau X. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer.

  24. Cosset JM, Cathelineau X, Wakil G, Pierrat N, Quenzer O, Prapotnich D, et al. Focal brachytherapy for selected low-risk prostate cancers: a pilot study. Brachytherapy. 2013;12(4):331–7.

    Article  PubMed  Google Scholar 

  25. De la Rosette T et al. Committee 4 Available Ablation Energies to Treat Prostate Cancer. In: Image-Guided Therapy for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Sanchez-Salas, R and Desai, M. [eds.] Melbourne, Australia. October 15–18, 2015. Available at: http://www.siu-urology.org/society/siu-icud. Forthcoming October 2016.

  26. Sivaraman A, Barret E. Focal therapy for prostate cancer: an “À la Carte” approach. Eur Urol. 2016;69(6):973–5.

    Article  PubMed  Google Scholar 

  27. Stern JM, Kibanov Solomonov VV, Sazykina E, Schwartz JA, Gad SC, Goodrich GP. Initial evaluation of the safety of nanoshell-directed photothermal therapy in the treatment of prostate disease. Int J Toxicol. 2016;35(1):38–46. doi:10.1177/1091581815600170.

    Article  PubMed  Google Scholar 

  28. Preise D, Scherz A, Salomon Y. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochem Photobiol Sci. 2011;10(5):681–8. doi:10.1039/c0pp00315h.

    Article  CAS  PubMed  Google Scholar 

  29. Azzouzi AR, Barret E, Bennet J, Moore C, Taneja S, Muir G, et al. TOOKAD® soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol. 2015;33(7):945–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Hu J, Xu H, Zhu W, et al. Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5194 patients. World J Surg Oncol. 2015;13:73.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Cussenot O, Cornu JN, Drouin SJ, Mozer P, Egrot C, Vaessen C, et al. Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. World J Urol. 2014;32(2):545–50. doi:10.1007/s00345-013-1196-y.

    Article  CAS  PubMed  Google Scholar 

  32. Barret E, Harvey-Bryan KA, Sanchez-Salas R, Rozet F, Galiano M, Cathelineau X. How to diagnose and treat focal therapy failure and recurrence? Curr Opin Urol. 2014;24(3):241–6.

    Article  PubMed  Google Scholar 

  33. Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2014;66(4):732–51.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Polascik T et al. Committee 5 Surveillance after Focal Therapy. In: Image-Guided Therapy for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Sanchez-Salas, R and Desai, M. [eds.] Melbourne, Australia. October 15–18, 2015. Available at: http://www.siu-urology.org/society/siu-icud. Forthcoming October 2016.

  35. Linares Espinós E, Sánchez-Salas R, Sivaraman A, Perez-Reggeti JI, Barret E, Rozet F, et al. Minimally invasive salvage prostatectomy after primary radiation or ablation treatment. Urology. 2016;94:111–6.

    Article  PubMed  Google Scholar 

  36. Duijzentkunst DA, Peters M, van der Voort van Zyp JR, Moerland MA, van Vulpen M .Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol. 2016 Mar 24. [Epub ahead of print].

Download references

Author information

Authors and Affiliations

  1. Department of Urology, L’Institut Mutualiste Montsouris, 42, Bd Jourdan, 75674, Paris Cedex 14, France

    Xavier Cathelineau & Rafael Sanchez-Salas

Authors
  1. Xavier Cathelineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rafael Sanchez-Salas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xavier Cathelineau.

Ethics declarations

Conflict of Interest

Xavier Cathelineau and Rafael Sanchez-Salas each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cathelineau, X., Sanchez-Salas, R. Focal Therapy for Prostate Cancer: Pending Questions. Curr Urol Rep 17, 86 (2016). https://doi.org/10.1007/s11934-016-0644-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-016-0644-9

Keywords

Search

Navigation